Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Kuittinen, E. Jantunen, E. Vanninen, H. Mussalo, O. Vuolteenaho, M. Ala-Kopsala, T. Nousiainen, J. Hartikainen (2006)
Cardiac effects within 3 months of BEAC high‐dose therapy in non‐Hodgkin's lymphoma patients undergoing autologous stem cell transplantationEuropean Journal of Haematology, 77
Youwu Shi, P. Liu, Shengyu Zhou, Jian-liang Yang, Xiaohong Han, Xiaohui He, Changgong Zhang, L. Gui, Y. Qin, Sheng Yang, Li-ya Zhao, Jiarui Yao, B. Jia, Shuxiang Zhang, Yan Sun, Yuankai Shi (2017)
Comparison of CBV, BEAM and BEAC high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non‐Hodgkin lymphoma: Efficacy and toxicityAsia‐Pacific Journal of Clinical Oncology, 13
T. Kuittinen, M. Husso-Saastamoinen, Petri Sipola, O. Vuolteenaho, M. Ala-Kopsala, T. Nousiainen, Esa Jantunen, Juha Hartikainen (2005)
Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantationBone Marrow Transplantation, 36
C. Geisler, A. Kolstad, A. Laurell, M. Jerkeman, R. Räty, N. Andersen, L. Pedersen, M. Eriksson, M. Nordström, E. Kimby, H. Bentzen, O. Kuittinen, G. Lauritzsen, H. Nilsson‐Ehle, E. Ralfkiær, M. Ehinger, C. Sundström, J. Delabie, M. Karjalainen‐Lindsberg, P. Brown, E. Elonen (2012)
Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occurBritish Journal of Haematology, 158
J. Jo, B. Kang, G. Jang, S. Sym, S. Lee, J. Koo, Jong Kim, S. Kim, J. Huh, C. Suh (2007)
BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicityAnnals of Hematology, 87
I. Sánchez-Ortega, G. Basak, E. Beohou, S. Werf, M. Labopin, A. Biezen, N. Kroeger, S. Montoto, A. Nagler, P. Dreger, H. Goldschmidt, D. Blaise, H. Einsele, J. Finke, N. Russell, M. Haenel, M. Potter, D. Caillot, H. Salwender, P. Ljungman, C. Craddock, L. Garderet, A. Sureda, M. Mohty, T. Ruutu, R. Duarte (2016)
Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMTBlood, 128
Yi-Bin Chen, A. Lane, B. Logan, Xiaochun Zhu, G. Akpek, M. Aljurf, A. Artz, C. Bredeson, K. Cooke, V. Ho, H. Lazarus, R. Olsson, W. Saber, P. McCarthy, M. Pasquini (2014)
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 21 6
E. Jantunen, C. Canals, A. Rambaldi, G. Ossenkoppele, B. Allione, D. Blaise, E. Conde, H. Tilly, G. Cook, F. Clark, A. Gallamini, A. Haynes, N. Mounier, P. Dreger, M. Pfreundschuh, A. Sureda (2008)
Autologous stem cell transplantation in elderly patients (≥60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registryHaematologica, 93
M. Caballero, Viñas Rubio, J. Rifón, Inmaculada Heras, Ramón García-Sanz, Lourdes Vázquez, B. Vidriales, M. Cañizo, M. Corral, Marcos González, A. León, E. Jean-Paul, Eduardo Rocha, J. Moraleda, J. Miguel (1997)
BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factorsBone Marrow Transplantation, 20
H. Fernandez, M. Escalón, D. Pereira, H. Lazarus (2007)
Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?Bone Marrow Transplantation, 40
Esa Jantunen, T. Kuittinen, T. Nousiainen (2003)
BEAC or BEAM for High-dose Therapy in Patients with Non-Hodgkin's Lymphoma? A Single Centre Analysis on Toxicity and EfficacyLeukemia & Lymphoma, 44
T. Philip, C. Guglielmi, A. Hagenbeek, Renier Somers, H. Lelie, D. Bron, P. Sonneveld, C. Gisselbrecht, J. Cahn, J. Harousseau, B. Coiffier, P. Biron, F. Mandelli, F. Chauvin (1995)
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.The New England journal of medicine, 333 23
A recent shortage of melphalan has prompted the use of alternatives to BEAM (BCNU, Etoposide, Cytarabine, Melphalan) conditioning for autologous stem cell transplantion (ASCT). The BEAC (BCNU, Etoposide, Cytarabine, Cyclophosphamide) regimen has been employed as a conditioning regimen in lymphoma patients. However, there have been recent concerns about the toxicity of BEAC. We conducted a retrospective analysis of the EBMT database comparing the outcome of patients conditioned using BEAC with a matched cohort of patients conditioned with BEAM. In the BEAC cohort (n = 383), 25 patients died from non-relapse mortality (NRM) events (32% owing to MOF or cardiac toxicity). In the BEAM cohort (n = 766) there were 34 NRM events (23% owing to MOF or cardiac toxicity). The 1-year cumulative incidence of NRM was 4% in the BEAC cohort and 3% in the BEAM group (p = ns). The 2-year relapse/progression rate was 32% with BEAC and 33% with BEAM (p = ns). At 2 years the progression-free survival (PFS) and overall survival (OS) were 63% and 78% for BEAC and 63% and 77% for BEAM-conditioned patients (p = ns for PFS and OS). The toxicity observed with BEAC conditioning as measured by NRM was similar to that seen with BEAM. The outcomes following BEAC were similar to those seen with BEAM, suggesting that BEAC is a safe conditioning regimen.
Bone Marrow Transplantation – Springer Journals
Published: Jun 8, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.